| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 50419-0397-01 | 50419-0397 | SEVABERTINIB | HYRNUO | 10.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | HER2, EGFR | Oral | Nov 19, 2025 | In Use | |
| 73207-0304-40 | 73207-0304 | Vimseltinib | ROMVIMZA | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R | Oral | Feb 14, 2025 | In Use | |
| 00597-0138-30 | 00597-0138 | Afatinib | Gilotrif | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug 8, 2013 | In Use | |
| 65162-0794-09 | 65162-0794 | Imatinib | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | In Use | |
| 43598-0344-10 | 43598-0344 | Imatinib | Imatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 13, 2018 | In Use | |
| 62332-0567-30 | 62332-0567 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
| 46708-0311-35 | 46708-0311 | Bosutinib | Bosutinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 19, 2026 | In Use | |
| 62332-0311-35 | 62332-0311 | Bosutinib | Bosutinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 19, 2026 | In Use | |
| 50419-0171-01 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sep 27, 2012 | In Use | |
| 31722-0296-90 | 31722-0296 | IMATINIB MESYLATE | IMATINIB MESYLATE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 14, 2025 | In Use | |
| 00310-0512-60 | 00310-0512 | Acalabrutinib | Calquence | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Oct 31, 2017 | In Use | |
| 59651-0547-30 | 59651-0547 | DASATINIB | DASATINIB | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
| 70710-1746-03 | 70710-1746 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 50242-0091-30 | 50242-0091 | ENTRECTINIB | Rozlytrek | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug 15, 2019 | In Use | |
| 68382-0913-06 | 68382-0913 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
| 63304-0093-27 | 63304-0093 | Sunitinib malate | Sunitinib malate | 37.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec 25, 2019 | In Use | |
| 43598-0456-46 | 43598-0456 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 19, 2025 | In Use | |
| 68001-0663-04 | 68001-0663 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 1, 2025 | In Use | |
| 00078-1091-94 | 00078-1091 | asciminib | SCEMBLIX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct 29, 2021 | In Use | |
| 00069-0830-38 | 00069-0830 | Sunitinib Malate | Sutent | 37.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Jul 12, 2014 | In Use | |
| 00093-8229-28 | 00093-8229 | Sunitinib Malate | Sunitinib Malate | 37.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec 22, 2021 | In Use | |
| 72485-0202-90 | 72485-0202 | imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 15, 2019 | In Use | |
| 68001-0665-04 | 68001-0665 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 5, 2025 | In Use | |
| 57962-0007-12 | 57962-0007 | Ibrutinib | Imbruvica | 70.0 mg/mL | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Aug 24, 2022 | In Use | |
| 00078-0640-70 | 00078-0640 | Ceritinib | Zykadia | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | Apr 29, 2014 | Feb 29, 2020 | In Use |
Found 12393 results — Export these results
Home